Moderna stock crashes 25%, loses about $24 billion after cancer vaccine data leak

Moderna’s stock price dropped over 25% after trial results for its personalized melanoma vaccine with Merck were disclosed. The decline erased approximately $24 billion from…

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (economictimes.indiatimes.com)